Sevion Therapeutics, Inc. – Retention Agreement (February 17th, 2015)
This Retention Agreement (this "Agreement") is made and entered into as of November 17, 2014 (the "Effective Date"), by and between Sevion Therapeutics, Inc., a Delaware corporation (the "Company") and Richard Dondero ("Executive").
Sevion Therapeutics, Inc. – Senesco Technologies, Inc. Indemnification Agreement (September 29th, 2014)
This Indemnification Agreement ("Agreement") is made as of May 25, 2010 by and between Senesco Technologies, Inc., a Delaware corporation (the "Company"), and Richard Dondero ("Indemnitee").
Sevion Therapeutics, Inc. – Supply Agreement (September 26th, 2008)
POLYPLUS-TRANSFECTION SA, a company organized under the laws of France (Polyplus), having its place of business at Bioparc, Boulevard Sebastien Brant, 67401 Illkirch (France) hereinafter referred to as SELLER or Seller
Sevion Therapeutics, Inc. – Master Product Sale Agreement (September 26th, 2008)
This MASTER PRODUCT SALE AGREEMENT (this Agreement) is entered into as of June 27, 2008 by and between Senesco Technologies Inc, a Delaware corporation having its principal place of business at 303 George Street, Suite 420, New Brunswick, NJ 08901 (CUSTOMER), and among VGXI, Inc., a Delaware corporation having an address of 2700 Research Forest Drive Suite 180, The Woodlands, Texas 77381, and VGX International, Inc. a Korean company having an address of Jung-Hun Building, #701, 944-1 Daechi 3-Dong, Gangnam-gu, Seoul, Korea, (collectively, VGX) with reference to the following facts:
Sevion Therapeutics, Inc. – Employment Agreement (September 28th, 2004)
THIS EMPLOYMENT AGREEMENT (this Agreement) is dated as of the 19th day of July, 2004, and is by and between Senesco, Inc., a New Jersey corporation with an office for purposes of this Agreement at 303 George Street, Suite 420, New Brunswick, New Jersey 08901 (hereinafter the Company or Employer), and Richard S. Dondero with an address at 37 Hillside Avenue, NJ 07457 (hereinafter the Employee).